Iradimed Corp. (IRMD)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1325618 · fiscal year ends in Dec
Closing price $85.81 on 29 Oct 2026; 52-week range $76.42 to $105.15.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $86.3M
- Revenue growth
- 11.2%
- Net income, last twelve months
- $23.1M
- Earnings per share
- $1.79
- Gross margin
- 75.9%
- Operating margin
- 31.9%
- Net margin
- 26.7%
- Free cash flow
- $25.1M
- Return on equity
- 22.7%
- Market value
- $1.1B
- Price to earnings
- 47.9x
- Cash
- $59.1M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 12.8M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $83.8M | $26.1M | $22.5M | $1.75 | $17.2M | 10-K filed 6 Mar 2026 |
| FY2024 | 31 Dec 2024 | $73.2M | $22.0M | $19.2M | $1.50 | $17.6M | 10-K filed 6 Mar 2025 |
| FY2023 | 31 Dec 2023 | $65.6M | $20.0M | $17.2M | $1.35 | $6.0M | 10-K filed 1 Mar 2024 |
| FY2022 | 31 Dec 2022 | $53.3M | $15.6M | $12.8M | $1.02 | $9.2M | 10-K filed 2 Mar 2023 |
| FY2021 | 31 Dec 2021 | $41.8M | $9.8M | $9.3M | $0.74 | $10.8M | 10-K filed 4 Mar 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q2 FY2026 | 30 Jun 2026 | $20.5M | $5.2M | $0.41 |
| Q1 FY2026 | 31 Mar 2026 | $22.0M | $5.8M | $0.45 |
| Q4 FY2025 | 31 Dec 2025 | $22.7M | $6.4M | $0.50 |
| Q3 FY2025 | 30 Sep 2025 | $21.2M | $5.6M | $0.43 |
| Q2 FY2025 | 30 Jun 2025 | $20.4M | $5.8M | $0.45 |
| Q1 FY2025 | 31 Mar 2025 | $19.5M | $4.7M | $0.37 |
| Q4 FY2024 | 31 Dec 2024 | $19.4M | $5.1M | $0.40 |
| Q3 FY2024 | 30 Sep 2024 | $18.3M | $5.0M | $0.40 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By region, FY2025
| Segment | Revenue | Share |
|---|---|---|
| United States | $70.6M | 84.2% |
| International | $13.3M | 15.8% |
Company events
The newest 8-K filings of 121 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 18 Aug 2026 | 8-K/A | Results | 2.02, 9.01 |
| 31 Jul 2026 | 8-K | Other events | 8.01 |
| 24 Jun 2026 | 8-K | Shareholder vote | 5.07 |
| 1 May 2026 | 8-K | Results | 2.02, 9.01 |
| 10 Feb 2026 | 8-K | Results | 2.02, 9.01 |
| 8 Dec 2025 | 8-K | Other events | 8.01, 9.01 |
| 3 Nov 2025 | 8-K | Results | 2.02, 9.01 |
| 2 Sep 2025 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 1 Aug 2025 | 8-K | Results | 2.02, 9.01 |
| 23 Jun 2025 | 8-K | Shareholder vote | 5.07 |
| 29 May 2025 | 8-K | Other events | 8.01, 9.01 |
| 5 May 2025 | 8-K | Results | 2.02, 9.01 |
Every filing
The newest filings with the SEC of 238 held.
| Filed | Form | Period |
|---|---|---|
| 18 Aug 2026 | 8-K/A | 31 Jul 2026 |
| 31 Jul 2026 | 10-Q | 30 Jun 2026 |
| 31 Jul 2026 | 8-K | 31 Jul 2026 |
| 24 Jun 2026 | 8-K | 24 Jun 2026 |
| 1 May 2026 | 10-Q | 31 Mar 2026 |
| 1 May 2026 | 8-K | 1 May 2026 |
| 30 Apr 2026 | ARS | 31 Dec 2025 |
| 30 Apr 2026 | DEF 14A | 23 Jun 2026 |
| 6 Mar 2026 | 10-K | 31 Dec 2025 |
| 10 Feb 2026 | 8-K | 10 Feb 2026 |
| 8 Dec 2025 | 8-K | 5 Dec 2025 |
| 3 Nov 2025 | 10-Q | 30 Sep 2025 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 3 Sep 2026 | Allen Monty K, Director | Sale outside a trading plan | 1,014 | $86.44 | $87.7K | 19,986 | 8 Sep 2026 |
| 3 Sep 2026 | Allen Monty K, Director | Sale outside a trading plan | 405 | $86.35 | $35.0K | 19,581 | 8 Sep 2026 |
| 4 Jun 2026 | Scharen-Guivel Hilda Frederique, Director | Sale outside a trading plan | 1,766 | $95.00 | $167.8K | 6,832 | 4 Jun 2026 |
| 4 Jun 2026 | Scharen-Guivel Hilda Frederique, Director | Sale outside a trading plan | 1,234 | $95.00 | $117.2K | 5,598 | 4 Jun 2026 |
| 1 Jun 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 400 | $88.68 | $35.5K | 2,164,600 | 2 Jun 2026 |
| 1 Jun 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 775 | $89.79 | $69.6K | 2,163,825 | 2 Jun 2026 |
| 1 Jun 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 401 | $91.08 | $36.5K | 2,163,424 | 2 Jun 2026 |
| 1 Jun 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 924 | $91.91 | $84.9K | 2,162,500 | 2 Jun 2026 |
| 27 May 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 2,167 | $91.85 | $199.0K | 2,165,333 | 28 May 2026 |
| 27 May 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 333 | $92.61 | $30.8K | 2,165,000 | 28 May 2026 |
| 26 May 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 3,111 | $91.81 | $285.6K | 2,169,389 | 28 May 2026 |
| 26 May 2026 | Susi Roger E., CEO, President, Chairman | Sale under a trading plan | 1,889 | $92.93 | $175.5K | 2,167,500 | 28 May 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 3 Sep 2026 | Monty K. Allen, Director | 1,419 | $122.6K | 3 Sep 2026 |
| 4 Jun 2026 | Hilda Scharen-Guivel, Director | 3,000 | $285.0K | 4 Jun 2026 |
| 6 Mar 2026 | Roger E. Susi, Officer, Director, 10% Stockholder | 100,000 | $9.9M | 6 Mar 2026 |
| 13 Feb 2026 | MONTY K. ALLEN, Director | 1,000 | $100.3K | 13 Feb 2026 |
| 11 Dec 2025 | JOHN GLENN, Officer | 15,000 | $1.5M | 11 Dec 2025 |
| 9 Dec 2025 | HAWKINS JAMES B, Director | 3,000 | $289.8K | 9 Dec 2025 |
| 20 Nov 2025 | JAMES B HAWKINS, Director | 3,000 | $264.7K | 20 Nov 2025 |
| 10 Nov 2025 | JOHN GLENN, Officer | 10,651 | $900.2K | 10 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 27 Oct 2026 | BlackRock, Inc. | 13G amended | 4.96% | 634.7K |
| 28 Jul 2026 | BlackRock, Inc. | 13G | 5.01% | 641.1K |
| 14 May 2026 | Roger E. Susi | 13G amended | 34.8% | 4.5M |
| 10 Feb 2026 | Nine Ten Capital Management | 13G amended | 3.4% | 428.5K |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 670.2K | +1.95% | 6.18 |
| 30 Sep 2026 | 657.4K | -6.09% | 4.5 |
| 15 Sep 2026 | 700.0K | +0.39% | 5.7 |
| 31 Aug 2026 | 697.3K | -4.19% | 8.38 |
| 14 Aug 2026 | 727.7K | +8.59% | 4.83 |
| 31 Jul 2026 | 670.2K | -5.05% | 5.77 |
| 15 Jul 2026 | 705.8K | +2.89% | 5.02 |
| 30 Jun 2026 | 686.0K | +0.62% | 4.85 |
Funds that hold it
From each fund's latest Form 13F.
242 funds held it at 30 Jun 2026: 112 added and 61 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 967,825 | $92.5M | +38 |
| Kayne Anderson Rudnick Investment Management LLC | 396,982 | $37.9M | +47,666 |
| Renaissance Technologies LLC | 394,412 | $37.7M | -46,300 |
| Copeland Capital Management, LLC | 391,860 | $37.4M | +32,535 |
| Vanguard Capital Management LLC | 364,937 | $34.9M | +6,317 |
| T. Rowe Price Investment Management, Inc. | 318,680 | $30.5M | +61,983 |
| Geode Capital Management, LLC | 290,109 | $27.7M | +3,546 |
| Nine Ten Capital Management LLC | 256,562 | $24.5M | -77,926 |
| Dimensional Fund Advisors LP | 229,340 | $21.9M | +3,194 |
| State Street Corp. | 221,512 | $21.2M | +16,984 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B